Central Panel Demands Banning Child Imagery on Medicine Packaging
In a major regulatory directive targeting paediatric health safety, an expert committee ruled that new cough syrup label rules must prohibit photos of infants, toddlers, or child-oriented cartoons on product packaging. The regulatory body concluded that child-friendly artwork creates a misleading impression that cough and cold formulations are safe for infants. To prevent misuse, the panel recommended mandating a red warning label on all liquid cough formulations. The text must explicitly state that the medicine should not be given to children under four years of age.
The Drugs Consultative Committee (DCC) evaluated the proposal submitted by its expert subcommittee. The advisory body approved the move to amend Rule 96 under the Drugs Rules, 1945, establishing strict packaging standards nationwide.
| Expert Panel Regulatory Review | Official Action Taken | Policy Objective |
| Child Imagery Directive | Prohibit cartoons, infant photos, and toddler illustrations | Eliminate misleading safety perceptions and improper sales |
| Statutory Label Requirement | Mandate high-contrast red warning text on cartons and bottles | Explicitly state “Not for use in children below 4 years” |
| Regulatory Framework | Amend Rule 96 under the Drugs Rules, 1945 | Enforce legally binding packaging standards nationwide |
Key Regulatory Directives and Safety Standards
| Regulatory Parameter | Official Panel Decision and Rule Changes |
| Governing Policy Directive | Strict cough syrup label rules prohibiting child imagery |
| Mandated Red Warning Text | “WARNING: Cough syrup shall not be used in children below 4 years of age.” |
| Legal Framework | Statutory amendment to Rule 96 of the Drugs Rules, 1945 |
| Regulatory Body | Drugs Consultative Committee (DCC) / CDSCO |
| Trigger Cause | Widespread off-label prescribing despite DGHS health advisories |
Continued Paediatric Over-Prescribing Drives Legal Enforcement
The decision follows growing concerns over the improper over-the-counter sale and prescription of cough formulations to young children. In October 2025, the Directorate General of Health Services (DGHS) issued an advisory urging doctors to avoid prescribing cough and cold drugs to infants under two years. However, healthcare audits revealed that clinicians continued prescribing these products to young toddlers.
An internal technical committee initially discussed placing photos of school-age children on bottles to signal the correct age group. However, the expert panel rejected that idea, noting that any child graphics confuse consumers and encourage improper usage in infants.
| Date Milestone | Regulatory Phase | Development and Statutory Action |
| October 2025 | DGHS Advisory | Health Ministry warns against prescribing cold meds to kids under 2 |
| April 2026 | Safety Evaluation | ICMR & CDSCO review paediatric health risk data |
| September 2026 | Technical Review | Subcommittee proposes prohibiting child graphics on packaging |
| October 2026 | DCC Approval | Panel approves mandatory red warnings and Rule 96 statutory updates |
Statutory Amendment to Enforce Prominent Red Warnings
Following the decision to enforce updated cough syrup label rules, regulatory authorities are finalizing statutory changes under the Drugs Rules, 1945. The updated draft rules require drug manufacturers to print the red warning prominently on outer cartons and bottle labels using a clearly legible font size. The label will read: “WARNING: Cough syrup shall not be used in children below 4 years of age.”
By introducing these mandatory labels, central regulators aim to ensure parents, pharmacists, and medical practitioners immediately recognize age restrictions before dispensing over-the-counter medications.
| Implementation Parameter | Statutory Mandate and Operational Rule |
| Warning Color Standard | High-contrast prominent red font displayed on outer packaging and bottle labels |
| Targeted Age Bracket | Strict prohibition enforced for all children under four years of age |
| Target Stakeholders | Drug manufacturers, retail pharmacists, paediatricians, and parents |
| Primary Legal Objective | Curb over-the-counter misuse and irrational paediatric prescribing |